UNSPSC 51285001: Clavulanate/ticarcillin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM113. This VA Drug Class (AM113) classifies this compound as belonging to the group EXTENDED SPECTRUM PENICILLINS.

UNSPSC 51285001 Clavulanate/ticarcillin is a Commodity code for a specific antibiotic combination product, but recent state and local procurement activity under this code shows limited direct alignment with the nominal scope. The two most recent opportunities posted under this code involve pharmaceutical procurement more broadly — one a completed piggyback contract through a cooperative purchasing vehicle for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), and another for naloxone and drug deactivation systems. State and local health departments and county health agencies appear to be the primary issuing bodies soliciting pharmaceutical supplies under related codes in this family, often leveraging cooperative purchasing consortia such as MMCAP Infuse to access volume pricing and pre-negotiated terms on pharmaceutical inventory.

Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for a 12-month initial term with two one-year renewal options, covering antibiotic tablet supply (IFB process, Solicitation 26482DPHPREPDB53392). Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The code shows activity in the Southeast and Midwest, though the sparse recent-opportunity record and the mismatch between the code's nominal scope (a specific antibiotic combination) and the actual work being bought (broader pharmaceutical supply, including vaccines and emergency-response drugs) suggests this Commodity code sees limited direct solicitation activity or may be misapplied to opportunities in related pharmaceutical families.